

**THRU ONLINE FILING**

September 24, 2025

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 023  
Scrip Code – 524494

National Stock Exchange India Limited,  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra – (East).  
Mumbai-400051.  
Scrip Code : IPCALAB

**Sub: Press / Media Release**

Dear Sir,

We are enclosing herewith copy of the press / media release issued by the Company w.r.t technology transfer of a monoclonal anti-body biosimilar being developed by the Company to M/s. Biosimilar Sciences PR LLC, USA.

Thanking you.

Yours faithfully  
For Ipca Laboratories Limited

Harish Kamath  
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.

[www.ipca.com](http://www.ipca.com)



---

## India to America Tech Transfer of a Monoclonal Antibody Biosimilar Supercharges Puerto Rico’s Biotech Hub

An Autoimmune and Cancer Targeting Biosimilar to Create U.S. Jobs, Secure Supply Chain with current US market of more than USD 4 Billion and expected to grow at 12% AGR.

San Juan, PR | Mumbai, IN [September 24<sup>th</sup>, 2025] Ipca Laboratories Ltd. (Ipca) (NSE: IPCA) and BioSimilar Sciences PR LLC (BSS) today announced a definitive **Technology Transfer and Joint Development Agreement** that will shift late-stage development, clinical manufacture, and commercial supply of a next generation anti-cancer / anti-inflammatory monoclonal antibody biosimilar being developed by Ipca to **BioSimilar Sciences PR LLC (BSS) 200,000 square feet sterile campus in Aguadilla, Puerto Rico.**

---

### Why these matters

Impact	What it means
<b>Multi-million in private U.S. investment</b>	Capital that would have been spent overseas now funds American jobs, infrastructure, and IP.
<b>Leverages 60 million units of Sterile Filling Capacity at OcyonBio</b>	Vials, syringes, and cartridges filled and finished under FDA oversight, tariff-free.
<b>Made in the USA</b>	Hundreds of high-paying jobs created in Puerto Rico.
<b>Reshored supply chain</b>	Reduces dependence on Asia and Europe; strengthens national readiness for essential medicines.
<b>Fast-track timeline</b>	First BSS biosimilar launches 2027; new molecule targets 2028/29 FDA approval.

---



### Executive quotes

#### Robert J. Salcedo, Co-Founder & CEO, BSS

“We’re turning decades of Indian innovation into American manufacturing muscle, exactly the sort of on-shoring that boosts the economy and puts life-saving biologics within reach of U.S. patients. This deal leverages BSS scientific capability while utilizing OcyonBio’s sterile filling capacity.”

#### Pranay Godha, MD & CEO, Ipca Laboratories

“By pairing Ipca’s established science with Puerto Rico’s skilled workforce and BSS’s regulatory expertise, we’re accelerating affordable biologics for people battling cancer and autoimmune disease worldwide.”

#### Daniel Chang, CFO & Co-Founder, BSS

“This transaction does more than add a product to our pipeline; it stitches together an **integrated, end-to-end biosimilar company**. Teaming Ipca’s development depth with BSS Research & Development and Ocyonbio’s U.S. **fill-finish 60 million capacity** lets us deliver **Made-in-America quality at globally competitive prices**. The India-Puerto Rico partnership is the economic engine that turns our mission *affordable medicines for the world* into reality.”

#### Ella Woger, CEO, Invest Puerto Rico & Board Member of International Economic Development Council

“This agreement underscores Puerto Rico’s growing strength as a global bioscience hub. By pairing world-class innovation with our legacy of advanced manufacturing, we are strengthening the nation’s life-saving medicine supply chain, and proving once again that Puerto Rico is the ideal destination for international companies seeking to compete and grow within the U.S. market.”

### Deal snapshot

Element	Details
License territory	Exclusive – USA & Canada • Non-exclusive –Some LATAM countries
Scope	Joint clinical development, full tech transfer, commercial manufacturing & launch
Licensing Fee	Ipca will receive defined milestone fees pertaining to Know-how/Technology transfer
Royalty	Ipca will receive Royalty on net sales upon commercialization of the product
U.S. hub	Biosimilar Sciences PR LLC and Ocyonbio, Aguadilla PR
Economic lift	Hundreds of skilled biotech jobs; expanded local supplier network and availability of affordable biosimilar drugs



---

### **About Ipca Laboratories Ltd.**

Established in 1949, Ipca is a pharmaceutical company with a strong thrust on exports which now account for nearly 50% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, Ipca has been a crucial healthcare partner in over 120 countries across the globe.

Today, Ipca is one of the world's largest manufacturers and suppliers of over a dozen APIs. These APIs are produced at manufacturing facilities approved by the world's most discerning drug regulatory authorities like US-FDA, EDQM-Europe, PMDA Japan and WHO-Geneva, among others.

In addition, Ipca is making significant strides in developing in-house capabilities in biosimilars / biologicals, with a specific emphasis on the development and commercialization of anti-cancer and anti-inflammatory monoclonal antibodies. Ipca has established a world class bio-manufacturing facility in Pithampur (MP) and state of the art R&D facility in Mumbai (MH) for its biosimilar development. These efforts are not just a continuation of the existing work, but rather a bold step forward into vital areas of healthcare.

This initiative is decidedly comprehensive, as Ipca strategically targets various key markets, including the USA, UK, EU, India, and the rest of the world (ROW). These advancements will enhance Ipca's product portfolio and substantially address significant healthcare needs across these regions, improving the quality of life for countless individuals.

### **About BioSimilar Sciences PR LLC**

BioSimilar Sciences PR LLC (BSS) is a pioneering biopharmaceutical company focused on addressing the affordability and accessibility challenges in the U.S. biologics market. With a mission to simplify and accelerate the entry of biosimilars, BSS has developed a proprietary Late-Entrant Simplify Strategy (LESS) to bring late-stage biosimilar assets efficiently through U.S. clinical, regulatory, and commercial pathways. This strategy enables BSS to bypass early development hurdles, focusing on scalable production and FDA approvals, which allows for faster market entry and reduced development risk.

BSS operates in close collaboration with its affiliate, OcyonBio, to leverage robust U.S.-based manufacturing capabilities. Through access to OcyonBio's large-scale fill-finish infrastructure, capable of producing up to 60 million units annually, BSS can provide cost-competitive, high-quality biologics that are entirely made within the United States. This ensures a secure, domestic



supply chain that supports drug availability while reinforcing economic development in Puerto Rico.

### **About OcyonBio Puerto Rico**

OcyonBio Puerto Rico is a state-of-the-art biomanufacturing platform and the Puerto Rico's first purpose-built biologics contract development and manufacturing organization (CDMO). Established to bridge the gap in advanced biologics production, OcyonBio offers integrated solutions for microbial and mammalian drug substance manufacturing, aseptic fill-finish operations, and real-time quality analytics. Its comprehensive suite of services is tailored to support the development, scale-up, and commercialization of cell and gene therapies, monoclonal antibodies, and other complex biologics.

OcyonBio plays a vital role in strengthening Puerto Rico's biotech ecosystem by fostering innovation, creating high-value jobs, and attracting global partnerships. It serves startups, mid-size biotech, and large pharmaceutical clients alike, offering flexible capacity and a collaborative model that supports rapid product development and market readiness. With its unique combination of infrastructure, expertise, and strategic location, OcyonBio is helping to redefine the future of biological manufacturing in the Americas and beyond.

---

### **Media contacts**

BSS: Daniel Chang [Daniel.chang@ocyonbio.com](mailto:Daniel.chang@ocyonbio.com)

Ipca: Corporate Communications | [corpcomm@ipca.com](mailto:corpcomm@ipca.com)

A handwritten signature in black ink, consisting of a series of loops and a long horizontal stroke at the end.